For research use only. Not for therapeutic Use.
Darunavir（Cat No.:I002590）is a potent HIV-1 protease inhibitor widely used in antiretroviral research and therapy. By binding to the active site of HIV protease, it prevents the cleavage of viral polyproteins, a critical step in viral replication, leading to the production of immature, non-infectious viral particles. Darunavir is particularly effective against resistant HIV strains due to its strong binding affinity and high genetic barrier to resistance. It serves as a cornerstone in studying protease inhibitor pharmacology, resistance pathways, and the optimization of combination antiretroviral therapies for HIV management.
| Catalog Number | I002590 |
| CAS Number | 206361-99-1 |
| Synonyms | (E)-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl hydrogen ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbonimidate |
| Molecular Formula | C27H37N3O7S |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Solubility | DMSO: soluble20 mg/mL, clear |
| Storage | Store at -20°C |
| Overview of Clinical Research | Darunavir is a HIV protease inhibitor developed by Gilead Sciences and Janssen R&D Ireland. |
| IUPAC Name | [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate |
| InChI | InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1 |
| InChIKey | CJBJHOAVZSMMDJ-HEXNFIEUSA-N |
| SMILES | CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N |
| Reference | <p style=”/line-height:25px/”> |
